How much ruxolitinib tablets should you take per day? Does the dose need to be adjusted according to different conditions?

Ruxolitinib tablets (JAKAVI, generic name: Ruxolitinib) is an oral Janus kinase inhibitor mainly used to treat myelofibrosis and some types of polycythemia vera. The drug slows down the progression of the disease and relieves related symptoms by inhibiting the JAK1 and JAK2 signaling pathways. The correct dosage depends on the patient's specific condition, disease course, weight, drug resistance and other factors. Dosage adjustment is crucial to ensure efficacy and reduce side effects.

For patients with myelofibrosis, the starting dose of ruxolitinib is generally 15mg twice daily, which is suitable for patients with moderate to severe myelofibrosis. For patients with lower body weight (< 50kg), a reduction to 10mg twice daily is usually recommended. This medication should be swallowed whole and should not be chewed or crushed to maintain the drug's release properties. Ruxolitinib can be taken with or without food, but to reduce gastrointestinal upset, it is best taken with food.

During treatment, the patient's efficacy and side effects will determine whether dosage adjustments are needed. Dosage adjustments may be required if patients experience serious side effects such as anemia, thrombocytopenia, or leukopenia. In these cases, doctors may adjust the dose based on the patient's blood results. For patients with mild side effects, the initial dose may be maintained, while for resistant patients, the dose may need to be gradually increased up to 20mg twice daily, but dosage increases must be guided and monitored by a physician.

During treatment, if the patient's disease pattern or symptoms change, the dose may require further adjustment. For example, in patients with polycythemia vera, the recommended dose of ruxolitinib is typically 10 mg twice daily, but may be adjusted to 15 mg twice daily based on the patient's specific circumstances. In addition, the dose also needs to be adjusted carefully when the patient's liver and kidney function are impaired. In those patients with severe hepatic impairment or renal failure, the initial dose may need to be reduced or excessive doses avoided.

Reference materials:https://www.jakavi.com/

xa0